We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Bindumalini Rao Baikady, PhD
02034376033
ASPIRE@icr.ac.uk
Aasia Hussain, PhD
02034376301
ASPIRE@icr.ac.uk
Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
This is in the inclusion criteria above
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Bindumalini Rao Baikady, PhD
02034376033
ASPIRE@icr.ac.uk
Aasia Hussain, PhD
02034376301
ASPIRE@icr.ac.uk
The study is sponsored by Institute of Cancer Research, United Kingdom and is in collaboration with Prostate Cancer UK; Janssen Pharmaceutica N.V., Belgium; Oncology Institute of Southern Switzerland; Syntrix Biosystems, Inc.; Royal Marsden NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Belfast Health and Social Care Trust; Institute of Oncology Research (IOR).
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
